Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 08, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital transactions.
- Shares Purchased: 1,930,000 ordinary shares.
- Purchase Price: 1,197.7658 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 8.99% of total voting rights).
- Shares in Issue: 5,271,861,896 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,930,000 shares purchased on July 08, 2008. Consequently, the total number of shares in issue was updated to 5,271,861,896. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the updated share count of 5,271,861,896 for calculating ownership percentages under Disclosure and Transparency Rules.
- Confirm the total Treasury share holding of 474,194,158 shares, which represents 8.99% of voting rights.
- Note that the repurchase price of 1,197.7658 pence per share reflects the market value at the time of the transaction on July 08, 2008.